Afsaneh Barzi, MD, PhD, City of Hope


Final Thoughts on Effective Therapy and Financial Toxicity

September 20th 2021

Experts in cancer management share their final thoughts on effective treatment and individualized care vs financial toxicity.

Innovation of Therapies vs Disruptive Pricing

September 20th 2021

A panel of experts debate the cost of innovation vs disruptive pricing of therapy.

Significance of PD-L1/PD-1 Testing in NSCLC

September 7th 2021

A panel of experts in cancer treatment review the need for PD-1/PD-L1 testing for immunotherapy.

Impact of Immunotherapy on Standard of Care for NSCLC and GI Cancers

August 30th 2021

Experts in cancer care management review PD-1/PD-L1 immunotherapy for patients with NSCLC and GI cancers.

Review of AENEAS Trial and Similar Agents

August 23rd 2021

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

EGFR-Targeted TKIs in NSCLC and Cost

August 23rd 2021

Mark Socinski, MD, Gilberto Lopes, MD, and Jack West, MD, provide an overview of the role of EGFR-targeted TKIs in NSCLC and the costs.

Impact of Payers on the Costs of Drugs

August 16th 2021

Jack West, MD, and Gilberto Lopes, MD, share their thoughts on the impact of payers when dealing with the cost of treatments.

Personalized Therapies Based on Innovation and Affordability

August 16th 2021

Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, discuss personalized treatment plans based on innovative therapies and affordability.

Role of Financial Toxicity on Treatment Decisions

August 9th 2021

Experts in various specialties of oncology management share their insights on the role of financial toxicity on making treatment decisions for patients.

Definition of Financial Toxicity

August 9th 2021

Jack West, MD, Gilberto Lopes, MD, and Afsaneh Barzi, MD, PhD, provide a definition for financial toxicity.